Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niku Singh

Psychiatry Falls Church, VA Medical Doctor

NPI 1558374595 CMS profile 24907

3300 Gallows Rd, Physician Billing, Falls Church, VA 22042

Open in the dashboard

General payments

$2,463,731

3,556 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Niku Singh of Falls Church, VA is reported in the CMS Open Payments database as having received $2,463,731 across 3,556 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $608,084 701
2024 General $468,842 610
2023 General $463,322 589
2022 General $426,739 609
2021 General $222,950 453
2020 General $122,063 262
2019 General $151,732 332

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niku Singh
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Niku Singh were reported at $608,084. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Niku Singh Psychiatry median Middle half National median
2019 $151,732 $184 $59–$605 $163
2020 $122,063 $119 $36–$372 $114
2021 $222,950 $143 $43–$576 $132
2022 $426,739 $153 $50–$590 $149
2023 $463,322 $170 $56–$651 $160
2024 $468,842 $179 $57–$673 $164
2025 $608,084 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $771,011 897 payments
  2. ITI, Inc. $593,560 640 payments
  3. Axsome Therapeutics, Inc. $317,587 345 payments
  4. Otsuka America Pharmaceutical, Inc. $296,360 453 payments
  5. Allergan Inc. $147,741 215 payments
  6. Alkermes, Inc. $143,352 182 payments
  7. E.R. Squibb & Sons, L.L.C. $120,273 132 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $42,981 106 payments
  9. Eisai Inc. $17,719 36 payments
  10. Ironshore Pharmaceuticals Inc. $2,860 117 payments
  11. Other $10,287 433 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,653,110 794 payments
  2. Travel and Lodging $451,397 1,051 payments
  3. Consulting Fee $182,012 72 payments
  4. Honoraria $109,275 38 payments
  5. Food and Beverage $67,692 1,591 payments
  6. Education $244 10 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $609,675 726 payments
  2. CAPLYTA Psychiatry $459,879 496 payments
  3. Auvelity $317,587 345 payments
  4. VRAYLAR Neuroscience $307,944 358 payments
  5. REXULTI $296,896 452 payments
  6. LYBALVI Cns $143,138 177 payments
  7. LYBALVI Cns $142,847 170 payments
  8. LYBALVI Cns $142,763 169 payments
  9. LYBALVI Cns $142,763 169 payments
  10. CAPLYTA Psychiatry $133,681 144 payments
  11. Other $194,118 974 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

403

Median for Psychiatry & Neurology: 100

Drug cost

$39,243

Median for Psychiatry & Neurology: $2,986

Branded share of claims

27.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 13 $13,672
Belsomra Suvorexant Brand 20 $10,512
Trintellix Vortioxetine Hydrobromide Brand 11 $7,053
Duloxetine Hcl Generic 47 $1,763
Quetiapine Fumarate Generic 64 $1,272
Bupropion Xl Bupropion Hcl Brand 25 $721
Clonazepam Generic 33 $614
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 29 $595
Clozapine Generic 12 $478
Aripiprazole Generic 26 $411

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$163,500 — —
CAPLYTA
$120,502 — —
Auvelity
$118,720 — —
REXULTI
$45,233 — —
LYBALVI
$14,920 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

3,556 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record